Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A southwest oncology group study

Journal of Clinical Oncology

Volumn 18, Issue 5, 2000, Pages 1043-1049

  Hussain, Maha ^a   Fisher, Emily I ^a   Petrylak, Daniel P ^a   O'Connor, John ^a   Wood, David P ^a   Small, Eric J ^a   Eisenberger, Mario A ^a   Crawford, E David ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; FLUTAMIDE; GOSERELIN; HYDROCORTISONE; LEUPRORELIN; SURAMIN;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034004368     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.5.1043     Document Type: Article

References (18)

1. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostate cancer. N Engl J Med 321:419-424, 1989
2. Hussain M, Crawford ED: Androgen deprivation strategies for metastatic prostate cancer, in Raghavan D, Scher HI, Leibel SA, et al (eds): Principles and Practice of Genitourinary Oncology. Philadelphia, PA, Lippincott-Raven, 1997, pp 591-598
3. Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1936-1042, 1998
4. Moscatelli D, Quarto N: Transformation of NIH-3T3 cells with basic fibroblast growth factor of the hst/K-fgf oncogene causes down-regulation of the fibroblast growth factor receptor: Reversal of morphological transformation and restoration of receptor number by suramin. J Cell Biol 109:2519-2527, 1989
5. Betsholtz C, Johnsson A, Heldin C, et al: Efficient reversion of simian sarcoma virus-transformation and inhibition of growth-factor-induced mitogenesis by suramin. Proc Natl Acad Sci U S A 83:6440-6444, 1986
6. Coffey R, Leof E, Shipley G, et al: Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol 132:143-148, 1987
7. Horne MKI, Stein CA, LaRocca RV, et al: Circulating glycosaminoglycan anticoagulants associated with suramin treatment. Blood 71:273-279, 1988
8. Hensey C, Boscoboinik D, Azzi A: Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett 258:156-158, 1989
9. Myers CE, Cooper MR, LaRocca RV, et al: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881-889, 1992
10. Kelly WK, Scher HI, Mazumdar M, et al: Suramin and hydrocortisone: Determining drug efficacy in androgen-independent prostate cancer. J Clin Oncol 13:2214-2222, 1995
11. Eisenberger MA, Sinibaldi VJ, Reyno LM, et al: Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone refractory prostate cancer. J Clin Oncol 13:2174-2186, 1995
12. Kobayashi K, Vokes EE, Vogelzang NJ, et al: Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13:2196-2207, 1995
13. Dawson NA, Cooper MR, Figg WD, et al: Antitumor activity of suramin in hormone refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76:453-462, 1995
14. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 371:1098-1109, 1993
15. Reyno LM, Egorin MJ, Eisenberger MA, et al: Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13:2187-2195, 1995
16. Small EJ, Marshall ME, Reyno L, et al: Superiority of suramin + hydrocortisone over placebo and hydrocortisone: Results of a multi-center double blind phase III study in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 17:308a, 1998 (abstr 1187)
17. Tong WP, Scher HI, Petrylak DP, et al: A rapid assay of suramin in plasma. J Liquid Chromatog 13:2269-2284, 1990
18. Dawson NA, Figg WD, Cooper MR, et al: Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 15:1470-1477, 1997